Active, not recruitingPhase 2NCT05287113
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Studying Squamous cell carcinoma of head and neck
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Biosciences International Sàrl
- Intervention
- Retifanlimab(drug)
- Enrollment
- 176 enrolled
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2022 – 2026
Study locations (30)
- Mayo Clinic Rochester, Scottsdale, Arizona, United States
- City of Hope National Medical Center, Duarte, California, United States
- City of Hope Orange County, Irvine, California, United States
- University of California San Diego Medical Center, Moores Cancer Center, La Jolla, California, United States
- City of Hope-Antelope Valley, Lancaster, California, United States
- Innovative Clinical Research Institute, Long Beach, California, United States
- City of Hope National Medical Center, Long Beach, California, United States
- University of California San Francisco Comprehensive Cancer Center, San Francisco, California, United States
- Georgetown University, Washington D.C., District of Columbia, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- Blessed Health Care, Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- University of Illinois At Chicago, Chicago, Illinois, United States
- University of Iowa, Iowa City, Iowa, United States
- University of Kansas Hospital Authority, Kansas City, Kansas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05287113 on ClinicalTrials.govOther trials for Squamous cell carcinoma of head and neck
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07333274Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE3NCT07026474Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCUniversität des Saarlandes
- RECRUITINGPHASE1NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNormunity AccelCo, Inc.
- RECRUITINGNANCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled TrialTobias Todsen
- RECRUITINGNANCT07180901Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck CancerCentre hospitalier de l'Université de Montréal (CHUM)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415Local Injection Methylene Blue Combined With Radiation in HNSCC PatientsChina Medical University Hospital
- RECRUITINGPHASE2NCT07088211Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- RECRUITINGPHASE2NCT07040956A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.West China Hospital
See all trials for Squamous cell carcinoma of head and neck →